An In-vivo Study into the Effects of Schisandrin B in the Liver, Spleen, Kidney, and Brain of Acute Thioacetamide-intoxicated Mice

Document Type : Research article


1 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.

2 Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan.

3 Ph.D. Program in Pharmacology and Toxicology, School of Medicine, Tzu Chi University, Hualien, Taiwan.



Currently, there are no effective treatments for liver diseases. Treatment usually involves controlling complications and supportive care. As liver injuries also affect other organs such as the spleen, kidney, and brain due to their anatomical and physiological relationships, finding an effective treatment is urgently needed. This research aimed to evaluate the therapeutic effect of Schisandrin B (Sch B) in the liver and other organs in thioacetamide (TAA)-intoxicated mice. In this study, mice were exposed to a single intraperitoneal injection of 200 mg/kg TAA to induce hepatitis. Following Sch B (20 mg/kg/day, 28 consecutive days) treatment, biochemistry analysis and histopathological examination of different organs were performed, in addition to western blotting and flow cytometry to evaluate the involvement of inflammasomes and apoptotic proteins. Our results showed that administration of Sch B protected against TAA-induced damages, and it disparately affected inflammasome activation and apoptosis in different organs. Furthermore, Sch B treatment improved organ function, as indicated by the improvement of serum biochemical parameters. Collectively, our findings reveal a beneficial effect of Sch B on different organ damages in mice intoxicated with TAA.

Graphical Abstract

An In-vivo Study into the Effects of Schisandrin B in the Liver, Spleen, Kidney, and Brain of Acute Thioacetamide-intoxicated Mice


(1) Uhl P, Fricker G, Haberkorn U and Mier W. Current
status in the therapy of liver diseases. Int. J. Mol.
Sci. (2014) 15: 7500-12.
(2) Tarantino G, Scalera A and Finelli C. Liver-spleen
axis: intersection between immunity, infections
and metabolism. World J. Gastroenterol. (2013)
19: 3534-42.
(3) Raj D, Tomar B, Lahiri A and Mulay SR. The gutliver-kidney axis: Novel regulator of fatty liver
associated chronic kidney disease. Pharmacol.
Res. (2020) 152: 104617.
(4) Butterworth RF. The liver-brain axis in liver
failure: neuroinflammation and encephalopathy.
Nat. Rev. Gastroenterol. Hepatol. (2013) 10: 522-
(5) Li L, Duan M, Chen W, Jiang A, Li X, Yang J and
Li Z. The spleen in liver cirrhosis: revisiting an old
enemy with novel targets. J. Transl. Med. (2017)
15: 111.
(6) Ferenci P. Hepatic encephalopathy. Gastroenterol.
Rep. (Oxf) (2017) 5: 138-47.
(7) Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W,
Inglada L, Navasa M, Clària J, Rimola A, Arroyo
V and Rodés J. Incidence, predictive factors, and
prognosis of the hepatorenal syndrome in cirrhosis
with ascites. Gastroenterology. (1993) 105: 229-
(8) Cooke JP. Inflammation and its role in regeneration
and repair: A caution for novel anti-inflammatory
therapies. Circ. Res. (2019) 124: 1166-8.
(9) Rathinam VAK and Chan FK-M. Inflammasome,
Inflammation, and Tissue Homeostasis. Trends
Mol. Med. (2018) 24: 304-18.
(10) Zheng D, Liwinski T and Elinav E. Inflammasome
activation and regulation: toward a better
understanding of complex mechanisms. Cell
Discov. (2020) 6: 36.
(11) Bauernfeind F, Ablasser A, Bartok E, Kim S,
Schmid-Burgk J, Cavlar T and Hornung V.
Inflammasomes: current understanding and open
questions. Cell Mol. Life Sci. (2011) 68: 765-83.
(12) Singh N and Bose K. Apoptosis: Pathways,
Molecules and Beyond. In: Bose K (ed.)
Proteases in Apoptosis: Pathways, Protocols and
Translational Advances. Springer International
Publishing, Cham (2015) 1-30.
(13) Jan R and Chaudhry GE. Understanding
apoptosis and apoptotic pathways targeted cancer
therapeutics. Adv. Pharm. Bull. (2019) 9: 205-18.
(14) Hartmann A, Hunot S, Michel PP, Muriel MP,
Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel
H, Srinivasan A, Ruberg M, Evan GI, Agid Y and
Hirsch EC. Caspase-3: A vulnerability factor and
final effector in apoptotic death of dopaminergic
neurons in Parkinson’s disease. Proc. Natl. Acad.
Sci. U.S.A. (2000) 97: 2875-80.
(15) Fulda S and Debatin KM. Extrinsic versus intrinsic
apoptosis pathways in anticancer chemotherapy.
Oncogene. (2006) 25: 4798-811.
(16) Leong PK and Ko KM. Schisandrin B: A DoubleEdged Sword in Nonalcoholic Fatty Liver Disease.
Oxid. Med. Cell. Longev. (2016) 2016: 6171658.
(17) Chu JH, Wang H, Ye Y, Chan PK, Pan SY, Fong
WF and Yu ZL. Inhibitory effect of schisandrin B
on free fatty acid-induced steatosis in L-02 cells.
World J. Gastroenterol. (2011) 17: 2379-88.
(18) Stacchiotti A, Li Volti G, Lavazza A, Rezzani
R and Rodella LF. Schisandrin B stimulates a
cytoprotective response in rat liver exposed to
mercuric chloride. Food Chem. Toxicol. (2009) 47:
(19) Li L, Zhang T, Zhou L, Zhou L, Xing G, Chen Y and
Xin Y. Schisandrin B attenuates acetaminopheninduced hepatic injury through heat-shock protein
27 and 70 in mice. J. Gastroenterol. Hepatol.
(2014) 29: 640-7.
(20) Zhu P, Li J, Fu X and Yu Z. Schisandra fruits for the
management of drug-induced liver injury in China:
A review. Phytomedicine (2019) 59: 152760.
(21) Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang J and
Zhang G. Schisandrin B attenuates CCl(4)-induced
liver fibrosis in rats by regulation of Nrf2-ARE
and TGF-β/Smad signaling pathways. Drug Des.
Devel. Ther. (2017) 11: 2179-91.
(22) Wu YF, Cao MF, Gao YP, Chen F, Wang T,
Zumbika EP and Qian KX. Down-modulation
of heat shock protein 70 and up-modulation of
Caspase-3 during schisandrin B-induced apoptosis
in human hepatoma SMMC-7721 cells. World J.
Gastroenterol. (2004) 10: 2944-8.
(23) Stacchiotti A, Li Volti G, Lavazza A, Schena I, Aleo
MF, Rodella LF and Rezzani R. Different role of
Schisandrin B on mercury-induced renal damage
Yin Pekkle Lam H et al. / IJPR (2021), 20 (4): 300-314
in vivo and in vitro. Toxicology. (2011) 286: 48-57.
(24) Lam PY and Ming Ko K. (−)Schisandrin B
ameliorates paraquat-induced oxidative stress by
suppressing glutathione depletion and enhancing
glutathione recovery in differentiated PC12 cells.
BioFactors (2011) 37: 51-7.
(25) Che F, Liu Y and Xu C. Prevention and treatment
of doxorubicin-induced cardiotoxicity by
dexrazoxane and schisandrin B in rabbits. Int. J.
Toxicol. (2011) 30: 681-9.
(26) Wallace MC, Hamesch K, Lunova M, Kim Y,
Weiskirchen R, Strnad P and Friedman SL.
Standard operating procedures in experimental
liver research: thioacetamide model in mice and
rats. Lab. Anim. (2015) 49: 21-9.
(27) Chen TM, Subeq YM, Lee RP, Chiou TW and
Hsu BG. Single dose intravenous thioacetamide
administration as a model of acute liver damage in
rats. Int. J. Exp. Pathol. (2008) 89: 223-31.
(28) Akahoshi T, Hashizume M, Tanoue K, Shimabukuro
R, Gotoh N, Tomikawa M and Sugimachi K.
Role of the spleen in liver fibrosis in rats may be
mediated by transforming growth factor beta-1. J.
Gastroenterol. Hepatol. (2002) 17: 59-65.
(29) Alomar MY. Physiological and histopathological
study on the influence of Ocimum basilicum leaves
extract on thioacetamide-induced nephrotoxicity in
male rats. Saudi J. Biol. Sci. (2020) 27: 1843-9.
(30) Peeling J, Shoemaker L, Gauthier T, Benarroch A,
Sutherland GR and Minuk GY. Cerebral metabolic
and histological effects of thioacetamide-induced
liver failure. Am. J. Physiol. (1993) 265: G572-8.
(31) Lam HYP, Liang TR, Jiang SJ and Peng SY.
Albendazole-Schisandrin B Co-Therapy
on Angiostrongylus cantonensis-Induced
Meningoencephalitis in Mice. Biomolecules.
(2020) 10.
(32) Zhu S, Wang Y, Chen M, Jin J, Qiu Y, Huang M and
Huang Z. Protective effect of schisandrin B against
cyclosporine A-induced nephrotoxicity in-vitro
and in-vivo. Am. J. Chin. Med. (2012) 40: 551-66.
(33) Giamarellos-Bourboulis EJ, Tziortzioti V,
Koutoukas P, Baziaka F, Raftogiannis M,
Antonopoulou A, Adamis T, Sabracos L and
Giamarellou H. Clarithromycin is an effective
immunomodulator in experimental pyelonephritis
caused by pan-resistant Klebsiella pneumoniae. J.
Antimicrob. Chemother. (2006) 57: 937-44.
(34) Melnikov VY, Faubel S, Siegmund B, Lucia MS,
Ljubanovic D and Edelstein CL. Neutrophilindependent mechanisms of caspase-1- and IL-18-
mediated ischemic acute tubular necrosis in mice.
J. Clin. Investig. (2002) 110: 1083-91.
(35) Sheldon RA, Jiang X, Francisco C, Christen
S, Vexler ZS, Täuber MG and Ferriero DM.
Manipulation of antioxidant pathways in neonatal
murine brain. Pediatr. Res. (2004) 56: 656-62.
(36) Colovai AI, Giatzikis C, Ho EK, Farooqi M, SuciuFoca N, Cattoretti G and Orazi A. Flow cytometric
analysis of normal and reactive spleen. Mod.
Pathol. (2004) 17: 918-27.
(37) Dotiwala AK, McCausland C, Samra NS. Anatomy,
Head and Neck, Blood Brain Barrier. StatPearls.
[Internet] 2021 Jan [cited: 2021 Mar 13] Available
from: URL:
(38) Zimmermann T, Müller A, Machnik G, Franke
H, Schubert H and Dargel R. Biochemical
and morphological studies on production and
regression of experimental liver cirrhosis induced
by thioacetamide in Uje: WIST rats. Zeitschrift fur
Versuchstierkunde. (1987) 30: 165-80.
(39) Watanabe A, Sohail MA, Gomes DA, Hashmi A,
Nagata J, Sutterwala FS, Mahmood S, Jhandier MN,
Shi Y, Flavell RA and Mehal WZ. Inflammasomemediated regulation of hepatic stellate cells. Am. J.
Physiol. Gastrointest. Liver Physiol. (2009) 296:
(40) Ghosh S, Sarkar A, Bhattacharyya S and Sil PC.
Silymarin protects mouse liver and kidney from
thioacetamide induced toxicity by scavenging
reactive oxygen species and activating PI3K-Akt
pathway. Front. Pharmacol. (2016) 7: 481.
(41) Rayamajhi M, Zhang Y and Miao EA. Detection
of pyroptosis by measuring released lactate
dehydrogenase activity. Methods Mol. Biol.
(Clifton, NJ) (2013) 1040: 85-90.
(42) Guo M, An F, Yu H, Wei X, Hong M and Lu Y.
Comparative effects of schisandrin A, B, and C
on Propionibacterium acnes-induced, NLRP3
inflammasome activation-mediated IL-1β secretion
and pyroptosis. Biomed. Pharmacother. (2017) 96:
(43) Leong PK and Ko KM. Schisandrin B induces
an Nrf2-mediated thioredoxin expression and
suppresses the activation of inflammasome in vitro
and in vivo. Biofactors. (2015) 41: 314-23.
(44) Tsarouchas TM, Wehner D, Cavone L, Munir T,
Keatinge M, Lambertus M, Underhill A, Barrett
T, Kassapis E, Ogryzko N, Feng Y, van Ham TJ,
Becker T and Becker CG. Dynamic control of
proinflammatory cytokines Il-1β and Tnf-α by
macrophages in zebrafish spinal cord regeneration.
Nat. Commun. (2018) 9: 4670.
(45) Chen Z, Guo M, Song G, Gao J, Zhang Y, Jing Z,
Liu T and Dong C. Schisandrin B inhibits Th1/
Th17 differentiation and promotes regulatory
T cell expansion in mouse lymphocytes. Int. 
Effects of Schisandrin B in Thioacetamide-intoxicated Mice
Immunopharmacol. (2016) 35: 257-64.
(46) Anders H-J and Muruve DA. The inflammasomes
in kidney disease. J. Am. Soc. Nephrol. (2011) 22:
(47) Tumani H, Hegen H, CSF Albumin: Albumin
CSF/Serum Ratio (Marker for Blood-CSF Barrier
Function). In: Deisenhammer F, Sellebjerg F,
Teunissen CE and Tumani H. (eds.) Cerebrospinal
Fluid in Clinical Neurology. 1st ed. Cham Springer
International Publishing (2015) 111-4.
(48) Forsberg P, Kam-Hansen S and Frydén A.
Production of specific antibodies by cerebrospinal
fluid lymphocytes in patients with herpes zoster,
mumps meningitis and herpes simplex virus
encephalitis. Scand. J. Immunol. (1986) 24: 261-
(49) Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ and
Berven FS. Proteomics of human cerebrospinal
fluid: discovery and verification of biomarker
candidates in neurodegenerative diseases using
quantitative proteomics. J. Proteomics. (2011) 74:
(50) Link H and Tibbling G. Principles of albumin and
IgG analyses in neurological disorders. II. Relation
of the concentration of the proteins in serum and
cerebrospinal fluid. Scand. J. Clin. Lab. Invest.
(1977) 37: 391-6.
(51) Seyfert S, Faulstich A and Marx P. What determines
the CSF concentrations of albumin and plasmaderived IgG? J. Neurol. Sci. (2004) 219: 31-3.